---
canonical_name: Stem Cell Educator Therapy
alternate_names: SCE Therapy, Educator Therapy, Stem Cell Educator, Gleukocell
canonical_topic: Stem Cell Educator Therapy for Health & Longevity
short_topic_lc: stem_cell_educator_therapy
creation_date: 2026-1120-0812
creator_ai_fullname: Opus 5.5
ep_keywords: Stem Cell Therapies, Cell Therapy, Apheresis, Leukapheresis, Cord Blood Stem Cells, Regenerative Medicine
---

# Stem Cell Educator Therapy for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 11/20/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5.5

**Also known as:** SCE Therapy, Educator Therapy, Stem Cell Educator, Gleukocell

  
## Motivation

<!-- This section was written only after the rest of the document was written, to have the full scope of the topic. -->

Stem Cell Educator therapy is an experimental procedure in which a person's own white blood cells are drawn out through a blood-cell separator, passed over donor stem cells taken from umbilical cord blood, and then returned to the bloodstream. The donor cells stay inside the device. The aim is to retrain an immune system that attacks the body's own tissues, rather than to suppress it.

The procedure was developed by one research group and its affiliated company. It has been studied mainly in diabetes, with small reports in an autoimmune form of hair loss and a few other immune-related conditions. Interest beyond these diseases comes from the broader idea of resetting the chronic, low-grade inflammation that rises with age and is linked to many age-related diseases.

This review examines what the human studies measured, how strong and how independent that evidence is, the risks of the procedure itself, how it is delivered and monitored, and what the ongoing trials could add, for proactive adults weighing an investigational immune therapy.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  
## Recommended Reading

<!-- Search (11/20/2026): web searches for "Stem Cell Educator" with each priority expert's name and with site: restrictions (foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com, lifeextension.com, lifespan.io), plus on-site searches of each platform. No priority expert has covered the therapy: Peter Attia, Chris Kresser and Lifespan.io on-site searches listed nothing relevant; the FoundMyFitness search returned only general stem cell episodes; the Life Extension and Huberman Lab on-site searches did not load, and their site: web searches returned no relevant item (Life Extension's 2026 regulatory T cell article does not discuss the therapy). General searches found the inventor's narrative reviews, a podcast interview with the inventor (excluded as a second item from the same expert), the Juvenile Diabetes Cure Alliance reports (2017, 2018, 2020; the latest is listed), and an independent patient-researcher blog. Mainstream media and company pages were excluded. -->

Overviews of the therapy from its inventor, a diabetes-cure advocacy group and an independent patient-researcher.

- [Stem Cell Educator therapy in type 1 diabetes: From the bench to clinical trials](https://pubmed.ncbi.nlm.nih.gov/35108619/) - Zhao et al., 2022

  The inventor's own narrative review of the device, the proposed immune mechanisms and the clinical trials in type 1 diabetes; useful for the full rationale, read with the author's financial stake in mind.

- [Practical Cure Update: Stem Cell Educator](https://www.thejdca.org/publications/report-library/archived-reports/2020-reports/practical-cure-update-stem-cell-educator.html) - Juvenile Diabetes Cure Alliance

  An outside assessment, from an advocacy group with no revenue stake in the therapy, of the program's mixed results, noting weaker responses in long-standing type 1 diabetes and the move toward recently diagnosed patients.

- [More Information on Zhao's Stem Cell Educator](https://cureresearch4type1diabetes.blogspot.com/2012/03/more-information-on-zhaos-stem-cell.html) - Joshua Levy

  A patient-researcher's questions to the investigators after the first trial, including skepticism that regrowth of insulin-producing cells could occur within weeks.

Only three items are listed: no further overview of the therapy met the inclusion criteria.

None of the priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io) has published content on Stem Cell Educator therapy; both web and on-site searches found none.

  
## Grokipedia

<!-- Search (11/20/2026): grokipedia.com searched directly for "Stem Cell Educator" and "Stem Cell Educator therapy Zhao". Results listed only general pages (Stem cell, Stem-cell therapy, Hematopoietic stem cell, Stem cell tourism); the direct page URL grokipedia.com/page/Stem_Cell_Educator returned 404. -->

No Grokipedia article on Stem Cell Educator therapy exists.

  
## Examine

<!-- Search (11/20/2026): examine.com searched directly for "stem cell educator" (results: Patchouli, Jiaogulan, HIV, Immune Health, glossary entry on systematic reviews) and a web search for "stem cell educator site:examine.com" (results: unrelated Examine pages). No article on the therapy. -->

No Examine article on Stem Cell Educator therapy exists. Examine.com covers supplements and nutrition and does not typically cover investigational cell-based procedures.

  
## ConsumerLab

<!-- Search (11/20/2026): consumerlab.com searched directly for "stem cell educator". Results listed unrelated product reviews and answers (hoodia, noni, graviola, hair serum, FTC coronavirus warning letters). No article on the therapy. -->

No ConsumerLab article on Stem Cell Educator therapy exists. ConsumerLab tests supplements and consumer products and does not typically cover investigational cell-based procedures.

  
## Systematic Reviews

<!-- Search (11/20/2026): PubMed searched for ("stem cell educator" OR "cord blood" OR "stem cell therapy" OR "cell therapy") AND diabetes AND (systematic review[pt] OR meta-analysis[pt]) (119 hits), and "stem cell educator" alone (23 hits, no systematic review). Full texts of candidate reviews were checked for inclusion of the Stem Cell Educator trials: Sun 2020 includes the 2012 type 1 diabetes trial; Wu 2020 includes the 2012 and 2015 type 1 diabetes trials; El-Badawy 2016, Li 2025 and Pires 2022 do not; Hwang 2019 mentions the trials only in its discussion. A search for systematic reviews of controlled umbilical cord blood studies found Aziz 2019, which includes the 2012 type 1 diabetes trial. -->

Three systematic reviews of stem cell or cord blood therapies include Stem Cell Educator trials; none evaluates this therapy on its own.

- [Systematic review of controlled clinical studies using umbilical cord blood for regenerative therapy: Identifying barriers to assessing efficacy](https://pubmed.ncbi.nlm.nih.gov/31587876/) - Aziz et al., 2019

  Covers 16 controlled cord blood studies, including the Stem Cell Educator trial; three type 1 diabetes studies showed no clear blood glucose or insulin-dose advantage.

- [Efficacy and Safety of Stem Cell Therapy for T1DM: An Updated Systematic Review and Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/33102605/) - Sun et al., 2020

  Pools 5 randomized and 8 non-randomized trials of stem cells in T1DM (type 1 diabetes mellitus), including the 2012 Stem Cell Educator trial.

- [Efficacy and safety of stem cells transplantation in patients with type 1 diabetes mellitus-a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/32321876/) - Wu et al., 2020

  Pools 29 stem cell studies in T1DM, including the 2012 Chinese and 2015 Spanish Stem Cell Educator trials, with pooled mortality and adverse-event rates.

None of the three reviews reports the risks of Stem Cell Educator therapy separately, so the risk side of the trade-off is unrepresented.

  
## Mechanism of Action

Apheresis (machine separation of blood components) processes about 10 liters of blood to isolate roughly 10 billion mononuclear cells (lymphocytes and monocytes, white blood cells that steer immunity) ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)). These cells flow for 2–3 hours over stacked discs coated with donor cord blood-derived multipotent stem cells (CB-SCs; umbilical cord blood cells able to become several cell types) and are then returned; the CB-SCs stay in the device ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)). Nearly all studies are led by the inventor, Yong Zhao, who holds an investment and fiduciary role in the licensing company ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)).

Proposed mechanisms, nearly all from the inventor's laboratory:

- **T cells:** CB-SCs express AIRE (autoimmune regulator, a gene teaching T cells to tolerate self-proteins) (inventor's review, [Zhao 2022](https://pubmed.ncbi.nlm.nih.gov/35108619/)) and PD-L1 (a "checkpoint" protein that switches off attacking T cells) ([Li 2015](https://pubmed.ncbi.nlm.nih.gov/25896390/)).
- **B cells:** galectin-9 (a sugar-binding surface protein) on CB-SCs suppresses antibody-producing B cells ([Hu 2024](https://pubmed.ncbi.nlm.nih.gov/38339108/)).
- **Monocytes:** exosomes (tiny signaling vesicles) from CB-SCs turn monocytes into anti-inflammatory M2 macrophages (repair-oriented immune cells) ([Hu 2020](https://pubmed.ncbi.nlm.nih.gov/32161585/)).
- **Platelets:** a second, laboratory-based hypothesis holds that platelet mitochondria (cell energy units) migrate to pancreatic islets (insulin-producing cell clusters) and support them ([Zhao 2017](https://pubmed.ncbi.nlm.nih.gov/28685960/)).

CB-SCs carry CD45 and CD11b (surface markers of blood immune cells) ([Descalzi-Montoya 2024](https://pubmed.ncbi.nlm.nih.gov/38307173/)), leaving open whether they act as stem cells or as regulatory immune cells. Nonspecific effects of extracorporeal (outside-the-body) processing remain possible, since only three people received sham processing ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)). Being a cell procedure, not a drug, it has no half-life or metabolic pathway.

  
## Historical Context & Evolution

Yong Zhao, then at the University of Illinois at Chicago, described CB-SCs in 2006 as cord blood cells with stem cell markers and very low immunogenicity (tendency to provoke an immune response) ([Zhao 2006](https://pubmed.ncbi.nlm.nih.gov/16716296/)). In 2009 his group reported that mouse regulatory T cells (immune cells restraining autoimmunity) co-cultured with CB-SCs reversed established autoimmune diabetes in non-obese diabetic mice ([Zhao 2009](https://pubmed.ncbi.nlm.nih.gov/19156219/)). The original intended use was therefore type 1 diabetes: stopping the immune attack on insulin-producing cells without broad immunosuppression.

The first human trial ([NCT01350219](https://clinicaltrials.gov/study/NCT01350219)), run in China and Spain from 2010, reported improved blood glucose control after one session ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)); Zhao invented the device and holds an investment and fiduciary role in the licensing company, a conflict the 2012 paper did not declare but a 2015 paper did ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)). Trials in type 2 diabetes ([Zhao 2013](https://pubmed.ncbi.nlm.nih.gov/23837842/)) and alopecia areata (autoimmune hair loss) ([Li 2015](https://pubmed.ncbi.nlm.nih.gov/25896390/)) followed.

What changed: the 2015 Spanish trial found C-peptide (a by-product that tracks the body's own insulin output) unchanged in people with no residual insulin production, unlike the Chinese results ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)), and later US work focused on recently diagnosed patients ([Throne FAQ](https://www.thronebio.com/frequently-asked-questions/)). Interest for health optimization grew as the company recast the procedure as a general "immune reset" ([Throne FAQ](https://www.thronebio.com/frequently-asked-questions/)) and extended it to long COVID (lasting post-infection symptoms) ([Zhao 2026](https://pubmed.ncbi.nlm.nih.gov/42949132/)) and Crohn's disease (inflammatory bowel disease) ([Fox 2025](https://pubmed.ncbi.nlm.nih.gov/40806424/)), where chronic inflammation is central. Its standing remains open: neither independent replication nor a large controlled trial has been published.

  
## Expected Benefits

<!-- Search (11/20/2026): PubMed searches for "stem cell educator" and for Zhao Y with CB-SC / platelet-derived mitochondria terms (all 27 hits screened); ClinicalTrials.gov searches for "Stem Cell Educator" (9 trials); web searches for clinical and expert commentary (Juvenile Diabetes Cure Alliance reports, patient-researcher blog, company pages); searches for meta-analyses of stem cell therapies in diabetes. Searches also targeted studies of any design showing no effect or opposite effects: the 2015 Spanish trial (no C-peptide gain without residual function) and the registry results of the US pilot (safety only, no efficacy outcomes). No study in healthy or ageing adults exists. -->

### High 🟩 🟩 🟩

No benefit reaches High: every human efficacy study comes from the inventor's research network, and only one included a sham-controlled comparison group, of three people.

### Medium 🟩 🟩

#### Better Glycemic Control and Insulin Production in Diabetes ⚠️ Conflicted

In a Chinese unblinded type 1 diabetes trial, 12 patients received one session and 3 were randomized to sham ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)); HbA1c (glycated hemoglobin, a 3-month average of blood glucose) fell ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)), insulin doses dropped 25–38% ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)) and C-peptide rose ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)). A Spanish two-session trial in the same network found C-peptide preserved only with residual insulin production ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)). In 36 adults with type 2 diabetes, an uncontrolled study reported lower HbA1c ([Zhao 2013](https://pubmed.ncbi.nlm.nih.gov/23837842/)). Net reading: one tiny sham-controlled trial suggests benefit; uncontrolled studies only partly agree.

**Magnitude:** In type 1 diabetes with residual insulin production, HbA1c went from 8.73% to 6.82% at 12 weeks, versus 9.0% to 8.7% with sham; not compared between groups ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)). In type 2 diabetes, HbA1c fell from 8.61% to 7.25% at 12 weeks (no control group) ([Zhao 2013](https://pubmed.ncbi.nlm.nih.gov/23837842/)).

### Low 🟩

#### Hair Regrowth in Alopecia Areata

Nine people with severe alopecia areata (autoimmune patchy or total hair loss) received one session, and regrowth began within 4 weeks in patchy and total-scalp forms ([Li 2015](https://pubmed.ncbi.nlm.nih.gov/25896390/)). The study was small and uncontrolled.

**Magnitude:** 2 of 9 participants reached complete regrowth at 12 and 16 weeks, sustained at 2 years (no control group) ([Li 2015](https://pubmed.ncbi.nlm.nih.gov/25896390/)).

#### Relief of Long COVID Fatigue and Brain Fog

In 25 people with long COVID (symptoms lasting 3 months or more after coronavirus infection), one session was followed by resolution of fatigue and brain fog in most ([Zhao 2026](https://pubmed.ncbi.nlm.nih.gov/42949132/)). This uncontrolled report cannot exclude placebo effects.

**Magnitude:** Brain fog and fatigue disappeared in 21 of 25 patients (no control group) ([Zhao 2026](https://pubmed.ncbi.nlm.nih.gov/42949132/)).

#### Remission of Crohn's Disease

A 78-year-old with long-standing Crohn's disease (chronic inflammatory bowel disease) had symptom, imaging and biopsy improvement after one session ([Fox 2025](https://pubmed.ncbi.nlm.nih.gov/40806424/)). A single case cannot separate treatment effect from natural fluctuation.

**Magnitude:** Normal bowel movements without pain or bleeding, and ileal (small-intestine) biopsies without inflammation at 5 weeks and 6 months; the literature reports no outcome figure beyond this single case (no control group) ([Fox 2025](https://pubmed.ncbi.nlm.nih.gov/40806424/)).

### Speculative 🟨

#### Lower Chronic Inflammation and Rebalanced Immune Cells

Patients showed more regulatory T cells ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)) and fewer IL-1β-positive cells (makers of interleukin-1 beta, an inflammatory signal) ([Zhao 2024](https://pubmed.ncbi.nlm.nih.gov/39125908/)). Age-related effects are untested; basis is unvalidated biomarkers.

#### Neuroprotection After Ischemic Stroke

In rats with induced ischemic stroke (stroke from blocked blood flow), infused lymphocytes co-cultured with CB-SCs reduced brain damage and neurological deficits ([Zhao 2019](https://pubmed.ncbi.nlm.nih.gov/31908436/)). No human stroke data exist; the basis is animal work only.

  
## Benefit-Modifying Factors

- **Residual insulin production:** C-peptide was preserved in people with some remaining insulin output but unchanged in those with none in the Spanish trial ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)).
- **Baseline inflammation:** People with high baseline IL-1β-positive cells and low GLUT2 (a glucose-sensing transporter) on blood insulin-producing cells showed marked shifts after treatment ([Zhao 2024](https://pubmed.ncbi.nlm.nih.gov/39125908/)); whether this predicts clinical response is untested.
- **Disease duration and ancestry:** Long-standing severe type 1 diabetes responded in Chinese but not Spanish participants; the authors could not explain the difference ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)).
- **Genetic polymorphisms:** No study has tested whether HLA type (inherited tissue-type markers) or other gene variants alter benefit.
- **Sex:** No sex-specific analysis exists; the US pilot enrolled 12 men and 1 woman ([NCT02624804](https://clinicaltrials.gov/study/NCT02624804)).
- **Age:** Trials enrolled ages 15–41 ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)), 18–58 ([NCT02624804](https://clinicaltrials.gov/study/NCT02624804)), the type 2 diabetes trial treated people up to age 68 ([Zhao 2013](https://pubmed.ncbi.nlm.nih.gov/23837842/)), and one 78-year-old case is reported ([Fox 2025](https://pubmed.ncbi.nlm.nih.gov/40806424/)); no age-specific analysis exists.

  
## Potential Risks & Side Effects

<!-- Search (11/20/2026): no prescribing information exists for this investigational procedure; the company FAQ (thronebio.com) lists tingling and numbness of fingers and lips and venipuncture discomfort. Reviewed: adverse events in all published trials and the posted results of NCT02624804 (ClinicalTrials.gov); apheresis safety literature (World Apheresis Association registry, citrate reaction studies); FDA consumer information on unapproved regenerative products. Searches also covered studies reporting no excess risk: the Chinese, Spanish and type 2 diabetes trials report no significant adverse events, and the 2012 trial's sham group underwent the same apheresis. -->

### High 🟥 🟥 🟥

No risk reaches High: adverse-event data come from small single-arm trials and one three-person sham group, with no trial from an independent research group.

### Medium 🟥 🟥

No risk reaches Medium: no trial compared adverse-event rates against an untreated or sham group of meaningful size, and apheresis registry data lack a comparison group.

### Low 🟥

#### Apheresis Discomfort and Citrate Reactions

Apheresis causes needle-site discomfort in most and arm soreness in some ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)). The US pilot recorded tingling, dizziness and near-fainting ([NCT02624804](https://clinicaltrials.gov/study/NCT02624804)); tingling reflects citrate anticoagulant (a calcium-binding clotting blocker) lowering blood calcium ([Adamski 2010](https://pubmed.ncbi.nlm.nih.gov/20818713/)). Severe reactions, often fainting from low blood pressure, interrupt 0.4% of procedures ([Mörtzell Henriksson 2016](https://pubmed.ncbi.nlm.nih.gov/26776481/)).

**Magnitude:** Tingling in 3 of 8, dizziness in 2 of 8 and near-fainting in 1 of 8 US participants ([NCT02624804](https://clinicaltrials.gov/study/NCT02624804)); mild apheresis effects in 5 of 25 and infusion itching in 1 of 25 long COVID patients ([Zhao 2026](https://pubmed.ncbi.nlm.nih.gov/42949132/)); severe reactions in 0.4% of 50,846 registry procedures ([Mörtzell Henriksson 2016](https://pubmed.ncbi.nlm.nih.gov/26776481/)); no control group in any.

#### Hypoglycemia After Treatment

Hypoglycemia (low blood glucose) affected 2 of 8 US pilot participants ([NCT02624804](https://clinicaltrials.gov/study/NCT02624804)). Insulin needs fell after treatment in the Chinese trial ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)), so unchanged doses could overshoot; usual type 1 diabetes variability may also explain events.

**Magnitude:** Hypoglycemia in 2 of 8 participants (no control group) ([NCT02624804](https://clinicaltrials.gov/study/NCT02624804)).

#### Serious Adverse Events

One of 8 US pilot participants had a serious adverse event (depression), and one had an unnamed treatment-related event ([NCT02624804](https://clinicaltrials.gov/study/NCT02624804)). The Spanish two-session trial reported no significant adverse events over 56 weeks ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)). Causality was not stated.

**Magnitude:** Serious adverse event in 1 of 8 participants (no control group) ([NCT02624804](https://clinicaltrials.gov/study/NCT02624804)).

### Speculative 🟨

#### Infection From Processing Outside the Body

Patient cells co-cultured for hours with donor cells could acquire microbial contamination or donor-borne infection; cord blood units are pathogen-screened ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)). No case is reported; basis is mechanistic.

#### Sensitization to Donor Tissue Types

Contact with donor cells could provoke antibodies against donor HLA, complicating later transplants. CB-SCs show low HLA-DR expression ([Descalzi-Montoya 2024](https://pubmed.ncbi.nlm.nih.gov/38307173/)); no recipient antibody testing is published, so basis is mechanistic.

#### Weakened Immune Defense

Shifting immune cells toward tolerance could blunt responses to infections or tumors. One US participant had a streptococcal throat infection ([NCT02624804](https://clinicaltrials.gov/study/NCT02624804)); no long-term infection or cancer tracking exists, so basis is isolated reports.

  
## Risk-Modifying Factors

- **First procedure:** Apheresis adverse events occur more often at the first procedure than later ones (8.4% versus 5.5%) in a 50,846-procedure registry ([Mörtzell Henriksson 2016](https://pubmed.ncbi.nlm.nih.gov/26776481/)).
- **Pre-existing conditions:** Multiple myeloma (a plasma-cell blood cancer) raised citrate reactions during leukapheresis (apheresis collecting white cells) (37% versus 20%) ([Adamski 2010](https://pubmed.ncbi.nlm.nih.gov/20818713/)); heart disease and low blood pressure raise the stakes of apheresis-related hypotension (low blood pressure) and arrhythmia (irregular heartbeat).
- **Baseline biomarkers:** Low baseline calcium, platelets or hemoglobin may amplify citrate reactions or the effect of extracorporeal blood volume; no study has tested this in this therapy.
- **Insulin regimen:** People on intensive insulin with tight targets face the largest hypoglycemia risk if insulin needs fall after treatment.
- **Genetic polymorphisms:** No variant is known to change procedural or immune risk; HLA sensitization risk is untested.
- **Sex:** No sex-specific data exist; women have smaller blood volumes, so extracorporeal volume is a larger share for small individuals.
- **Age:** Older adults with heart disease or fragile veins tolerate long apheresis less well; the type 2 diabetes trial treated participants up to age 68 without significant adverse events ([Zhao 2013](https://pubmed.ncbi.nlm.nih.gov/23837842/)), and one 78-year-old case is reported ([Fox 2025](https://pubmed.ncbi.nlm.nih.gov/40806424/)).

  
## Key Interactions & Contraindications

<!-- Search (11/20/2026): PubMed searched for "stem cell educator" AND ("drug interaction" OR pharmacokinetics OR interaction) (one hit, no interaction data), and for interactions of apheresis with ACE inhibitors and with calcium supplementation. No human interaction or pharmacokinetic study of the therapy exists; documented items rest on dose changes reported in the trials and on apheresis studies. -->

**Documented interactions:**

- **Insulin:** Insulin doses fell 25–38% after treatment ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)), so unchanged doses risk hypoglycemia. Frequent glucose monitoring with clinician-led dose reduction mitigates this.
- **Metformin:** Daily metformin doses were reduced after treatment in type 2 diabetes ([Zhao 2013](https://pubmed.ncbi.nlm.nih.gov/23837842/)); continued full dosing adds glucose lowering. Dose review at 4 and 12 weeks mitigates this.
- **Oral calcium, vitamin D3 and magnesium (supplements):** Prophylactic intake eliminated citrate reactions during stem cell apheresis (0 of 26 versus 8 of 26) ([Fujii 2026](https://pubmed.ncbi.nlm.nih.gov/42947394/)); oral calcium alone showed no significant reduction ([Abe 2024](https://pubmed.ncbi.nlm.nih.gov/39358092/)).

**Theoretical interactions (inferred from mechanism, not studied in humans):**

- **ACE inhibitors (blood-pressure drugs that block angiotensin-converting enzyme; lisinopril, enalapril):** Inferred from bradykinin (a vessel-dilating peptide) build-up: allergic-like reactions, reported only with column-based cholesterol-removing apheresis ([Koga 1993](https://pubmed.ncbi.nlm.nih.gov/8268545/)), not with centrifugal cell separation. Withholding the drug beforehand mitigates this.
- **Sulfonylureas and other oral glucose-lowering drugs (drugs that lower blood glucose; glipizide, glimepiride, repaglinide):** Inferred from additive glucose lowering if the body's own insulin output recovers: hypoglycemia. Glucose monitoring with prescriber-led dose review mitigates this.
- **Immunosuppressants and immune biologics (drugs that dampen immune activity, including antibody-based ones; prednisone, tacrolimus, methotrexate, teplizumab):** Inferred from overlapping immune mechanisms: they could blunt the intended immune "education" or add immunosuppression with infection risk. Timing relative to the session is undefined.
- **Anticoagulants and antiplatelet drugs (drugs that slow clotting or block platelet clumping; warfarin, apixaban, clopidogrel):** Inferred from impaired clotting at the two large-bore needle sites: bruising or bleeding. Prior review of dosing with the prescriber mitigates this.
- **Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs; aspirin, ibuprofen, naproxen):** Inferred from platelet inhibition: more bleeding at puncture sites. Pausing non-essential use for a few days beforehand mitigates this.
- **Blood-pressure-lowering drugs (amlodipine, metoprolol):** Inferred from additive blood pressure lowering during extracorporeal volume shifts: dizziness or fainting. Vital-sign monitoring during apheresis mitigates this.
- **Antiplatelet supplements (fish oil, high-dose vitamin E, ginkgo):** Inferred from additive antiplatelet effects: bleeding at access sites. Pausing several days beforehand mitigates this.
- **Immune-modulating supplements (high-dose vitamin D, curcumin):** Inferred from overlapping effects on regulatory T cells and inflammatory cytokines: confounded immune-marker monitoring. Stable intake across baseline and follow-up mitigates this.
- **Vaccination:** Inferred from a tolerance-oriented immune shift: possibly weaker vaccine responses. Spacing vaccines a few weeks from the session mitigates this.
- **Blood donation or other apheresis:** Inferred from cumulative blood-cell loss: anemia or low platelets. Spacing procedures and checking blood counts mitigates this.

**Populations who should avoid Stem Cell Educator Therapy:**

- **Hemodynamic instability (unstable blood pressure or circulation) or severe heart disease (e.g., New York Heart Association class III–IV heart failure, symptoms with minimal activity or at rest):** Severe apheresis reactions include hypotension and arrhythmia ([Mörtzell Henriksson 2016](https://pubmed.ncbi.nlm.nih.gov/26776481/)); avoidance in these groups is inferred.
- **Multiple myeloma or known hypocalcemia (low blood calcium), which predispose to citrate toxicity:** Citrate reactions are more frequent in multiple myeloma ([Adamski 2010](https://pubmed.ncbi.nlm.nih.gov/20818713/)); avoidance with known hypocalcemia is inferred from citrate's calcium-lowering effect; no human data.
- **Pregnancy:** Inferred from untested immune modulation and prolonged apheresis during pregnancy; no human data.
- **Active infection:** Inferred from the possibility that a tolerance-oriented immune shift weakens infection control; no human data.
- **People awaiting organ or stem cell transplantation:** Inferred from possible donor-HLA sensitization; no human data.

  
## Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

- **Trial enrollment:** Receiving the procedure only within a registered, FDA (US Food and Drug Administration)-overseen trial such as [NCT04011020](https://clinicaltrials.gov/study/NCT04011020) mitigates unverified cell quality and missing adverse-event follow-up.
- **Calcium, vitamin D3 and magnesium before apheresis:** Prophylactic oral supplementation prevents citrate tingling and tetany (painful muscle spasms) ([Fujii 2026](https://pubmed.ncbi.nlm.nih.gov/42947394/)).
- **Hydration and a meal before the session:** Drinking fluids and eating beforehand reduces dizziness and near-fainting during 6–9 hours of apheresis.
- **Vital signs and cardiac monitoring:** Regular vital-sign checks, cardiac monitoring and nearby emergency equipment mitigate severe apheresis hypotension and arrhythmia ([Mörtzell Henriksson 2016](https://pubmed.ncbi.nlm.nih.gov/26776481/)).
- **Continuous glucose monitoring for 12 weeks:** Prevents hypoglycemia as insulin needs fall; time below 70 mg/dL above 4% calls for reducing therapy ([American Diabetes Association 2025](https://pubmed.ncbi.nlm.nih.gov/39651981/)), whose clinician members earn no direct revenue from this target.
- **No unsupervised insulin withdrawal:** Keeping basal (long-acting background) insulin until C-peptide and glucose data justify reduction prevents diabetic ketoacidosis (life-threatening acid build-up from insulin lack).
- **Medication review one week before:** Adjusting anticoagulants, antiplatelets and NSAIDs with the prescriber reduces bleeding at the two needle sites.
- **Cord blood screening records:** Confirming donor units were screened for HIV (human immunodeficiency virus), hepatitis B and C and other pathogens ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)) mitigates donor-borne infection.
- **HLA antibody screen for transplant candidates:** Testing before and 3–6 months after treatment detects donor sensitization early.

  
## Therapeutic Protocol

Parameters other than cited doses (timing, scheduling, re-treatment intervals) reflect common practice.

- **Closed-loop single session (inventor's protocol):** Apheresis at 35 mL/min for 6–7 hours, 2–3 hours of co-culture in the device, then return of cells through a hand vein ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)).
- **Cell dose:** About 10 liters of blood processed, yielding roughly 10 billion mononuclear cells, exposed to about 10 million CB-SCs at ratios of 1:20 to 1:50 ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)).
- **Single versus split sessions:** Chinese trials used one session ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/); [Zhao 2013](https://pubmed.ncbi.nlm.nih.gov/23837842/); [Li 2015](https://pubmed.ncbi.nlm.nih.gov/25896390/)); the Spanish trial added a second at 3 months to reach cells sheltered in lymph nodes ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)).
- **Re-treatment interval:** The company states severe cases may receive another session 6–12 months later, guided by immune-cell profiling ([Throne FAQ](https://www.thronebio.com/frequently-asked-questions/)), differing from the 3-month interval above.
- **Open-loop variant:** Day one collects about 250 mL of white cells over 4–5 hours; cells incubate 17 hours in the device and are reinfused on day two ([Throne FAQ](https://www.thronebio.com/frequently-asked-questions/)).
- **Popularizing group:** Developed by Yong Zhao, whose company Tianhe Stem Cell Biotechnologies licensed it ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)); Throne Biotechnologies sponsors the trials ([NCT01350219](https://clinicaltrials.gov/study/NCT01350219)), and Hackensack Meridian Health sponsored the US pilot ([NCT02624804](https://clinicaltrials.gov/study/NCT02624804)).
- **Competing approaches for type 1 diabetes:** Insulin targeting HbA1c below 7% ([American Diabetes Association 2025](https://pubmed.ncbi.nlm.nih.gov/39651981/); members earn no direct revenue from it); teplizumab (an antibody that dampens T cells) delaying onset ([Herold 2019](https://pubmed.ncbi.nlm.nih.gov/31180194/)); stem cell-derived islet infusion ([Reichman 2025](https://pubmed.ncbi.nlm.nih.gov/40544428/)).
- **Time of day:** Sessions start in the morning because they last 8–10 hours, with overnight observation; no time-of-day effect has been studied.
- **Half-life:** Not applicable to a cell procedure; how long educated cells persist is unknown, while immune-cell shifts were tracked to 56 weeks ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)).
- **Genetic polymorphisms:** No donor-recipient HLA matching is used, based on the low immunogenicity of CB-SCs ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)); no gene variant guides protocol choice.
- **Sex:** No sex-based dosing or response differences have been studied.
- **Age:** Trials enrolled 15–41 years ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)), 18–58 years ([NCT02624804](https://clinicaltrials.gov/study/NCT02624804)) and up to 68 years in type 2 diabetes ([Zhao 2013](https://pubmed.ncbi.nlm.nih.gov/23837842/)), plus one 78-year-old case ([Fox 2025](https://pubmed.ncbi.nlm.nih.gov/40806424/)); the US phase 3 trial admits ages 10 and older ([NCT04011020](https://clinicaltrials.gov/study/NCT04011020)).
- **Baseline biomarkers:** Measurable fasting C-peptide marks the subgroup with preserved response ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)).
- **Pre-existing conditions:** Recently diagnosed type 1 diabetes is the current target population, per the company's designation for recent-onset patients ([Throne FAQ](https://www.thronebio.com/frequently-asked-questions/)).

  
## Discontinuation & Cycling

- **One-time versus ongoing:** The procedure is a one- or two-session treatment, not a continuous therapy; durability claims rest on 4-year follow-up of a few Chinese patients ([Zhao 2017](https://pubmed.ncbi.nlm.nih.gov/28685960/)).
- **Withdrawal effects:** None are described; no drug is taken between sessions.
- **Tapering:** Not applicable to the procedure itself; any reduction of insulin or oral glucose-lowering drugs afterward is stepwise and guided by glucose data.
- **Cycling:** No evidence supports cycling; repeat sessions are proposed at 3 months ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)) or 6–12 months ([Throne FAQ](https://www.thronebio.com/frequently-asked-questions/)).
- **Waning response:** In the Spanish trial, C-peptide dipped at 26 weeks before recovering at 40 weeks in two participants ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)), so a single low reading is not proof of failure.

  
## Sourcing and Quality

- **Single licensed source:** The device and CB-SC culture are licensed from the University of Illinois at Chicago to the inventor's company ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)); no other producer exists.
- **Cord blood origin:** Fresh units from cord blood banks, screened for HIV, hepatitis and other pathogens, are cultured 2–3 weeks to about 10 million CB-SCs per device ([Delgado 2015](https://pubmed.ncbi.nlm.nih.gov/26844283/)).
- **Personal cord blood:** The company does not use privately stored cord blood ([Throne FAQ](https://www.thronebio.com/frequently-asked-questions/)).
- **Look-alike offers:** Clinics selling "stem cell immune resets" are not this procedure; the FDA warns that cord blood products sold outside FDA-overseen trials are unapproved ([FDA consumer information](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies)).
- **What to look for:** A registered trial number, an investigational new drug (IND, FDA permission to test an unapproved product) number, consent approved by an institutional review board (ethics committee), and a hospital apheresis unit.

  
## Practical Considerations

- **Time to effect:** HbA1c changes appeared at 4–12 weeks ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)) and hair regrowth from 4 weeks ([Li 2015](https://pubmed.ncbi.nlm.nih.gov/25896390/)).
- **Common pitfalls:** Stopping insulin early; treating company claims ("tested in more than 300 patients", [NCT04011020](https://clinicaltrials.gov/study/NCT04011020)) as published data, which cover far fewer people; mistaking unlicensed stem cell clinics for this procedure.

<!-- Regulator pages checked (11/20/2026): FDA Approved Cellular and Gene Therapy Products list (no Stem Cell Educator or Throne entry); FDA RMAT designation page (eligibility criteria, cumulative request counts and RMAT approvals; no product-level designation list). -->

- **Regulatory status:** Not FDA-approved: absent from the FDA's list of licensed cellular and gene therapy products ([FDA approved products list](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products)); the company confirms it is not commercially available ([Throne FAQ](https://www.thronebio.com/frequently-asked-questions/)).
- **RMAT designation:** Throne reports Regenerative Medicine Advanced Therapy (RMAT, an FDA expedited-review program) designation for type 1 diabetes in April 2024 ([Throne press release](https://www.thronebio.com/throne-received-fda-approval-on-regenerative-medicine-advanced-therapy-rmat-designation-by-using-stem-cell-educator-therapy-to-treat-type-1-diabetes/)); FDA confirmation not yet posted, as its RMAT page lists no individual designations ([FDA RMAT page](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenerative-medicine-advanced-therapy-designation)).
- **Access pathways:** Available only through trials or, per the company, the federal Right to Try pathway ([Throne FAQ](https://www.thronebio.com/frequently-asked-questions/); [FDA Right to Try page](https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try)).
- **Cost and logistics:** No price is published; a session takes 8–10 hours, often over two days, at a single US site, with five follow-up visits in the current trial ([Throne FAQ](https://www.thronebio.com/frequently-asked-questions/)).
- **Payer incentives:** A one-time procedure competing with lifelong insulin and devices gives insurers a financial interest in its outcome either way, a potential structural bias in coverage and research funding.

  
## Interaction with Foundational Habits

- **Sleep:** Direction: none established. No study measured sleep; long COVID patients reported feeling refreshed and energized ([Zhao 2026](https://pubmed.ncbi.nlm.nih.gov/42949132/)), but this is uncontrolled. Rest before the long session is common practice.
- **Nutrition:** Direction: indirect. If insulin needs fall, carbohydrate-to-insulin ratios need recalibration to avoid hypoglycemia. A single calcium drink before apheresis did not significantly reduce citrate reactions ([Abe 2024](https://pubmed.ncbi.nlm.nih.gov/39358092/)), whereas combined calcium, vitamin D3 and magnesium did ([Fujii 2026](https://pubmed.ncbi.nlm.nih.gov/42947394/)); no diet is known to enhance the immune effect.
- **Exercise:** Direction: potentiating for glucose lowering. Exercise lowers blood glucose, adding to any post-treatment fall in insulin needs; glucose checks around workouts reduce hypoglycemia. Heavy arm exertion is avoided for a day after the needle insertions.
- **Stress management:** Direction: none studied. Chronic stress raises inflammatory markers, which could confound the immune-marker follow-up used to judge response; no study measured cortisol or stress responses after treatment.

  
## Monitoring Protocol & Defining Success

Before starting, a baseline panel documents insulin production, glucose control and procedural safety: fasting and stimulated C-peptide, HbA1c, two weeks of continuous glucose monitoring (CGM) data, daily insulin dose, a complete blood count with platelets, and, for transplant candidates, an HLA antibody screen. Baseline photographs suit alopecia areata, and symptom scores suit long COVID.

Ongoing monitoring follows the trial schedules: at 4 weeks, 12 weeks, 24 weeks and 40 weeks after the session ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)), then every 6–12 months. Continuous glucose monitoring runs throughout the first 12 weeks, when insulin needs changed most. Success is defined as a sustained rise or preserved level of C-peptide with stable or lower HbA1c on less insulin, without more hypoglycemia; immune-cell profiles are supportive, not decisive.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Fasting C-peptide | 0.3–3.3 ng/mL (standard reference range) | Expected to change: own insulin output | Fasting sample with simultaneous glucose; pair with stimulated C-peptide; source [MedlinePlus C-peptide test](https://medlineplus.gov/ency/article/003701.htm) |
| HbA1c | Below 7% (American Diabetes Association goal) | Expected to change: 3-month glucose average | HbA1c = glycated hemoglobin; guideline target, not a reference range ([American Diabetes Association 2025](https://pubmed.ncbi.nlm.nih.gov/39651981/)); the association's clinician members earn no direct revenue from this target; no fasting needed |
| CGM time in range (70–180 mg/dL) | Above 70% (American Diabetes Association goal) | Expected to change: daily glucose control | CGM = continuous glucose monitoring; guideline target ([American Diabetes Association 2025](https://pubmed.ncbi.nlm.nih.gov/39651981/)); members earn no direct revenue from it; 14 days of data |
| CGM time below 70 mg/dL | Below 4% (American Diabetes Association goal) | Safety check: hypoglycemia as insulin needs fall | Guideline target ([American Diabetes Association 2025](https://pubmed.ncbi.nlm.nih.gov/39651981/)); members earn no direct revenue from it; above it, therapy is reduced |
| Regulatory T cells (CD4⁺CD25⁺FOXP3⁺) | No established target; track change from own baseline | Expected to change: proposed immune mechanism | Research flow cytometry (laser-based cell counting) only ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)); CD4⁺CD25⁺FOXP3⁺ = surface and nuclear markers defining regulatory T cells |
| Platelet count | 150–400 × 10⁹/L (standard reference range) | Safety check: apheresis blood-cell loss | Part of a complete blood count; check before and 24 hours after; source [MedlinePlus platelet count](https://medlineplus.gov/ency/article/003647.htm) |

Qualitative markers:

- Frequency and severity of hypoglycemia episodes and hypoglycemia awareness
- Energy, fatigue and mental clarity, especially after long COVID
- Hair regrowth on standardized photographs in alopecia areata
- Bowel symptoms in inflammatory bowel disease
- Frequency of infections in the year after treatment

  
## Emerging Research

- **US phase 3 type 1 diabetes trial ([NCT04011020](https://clinicaltrials.gov/study/NCT04011020)):** Single-arm, about 80 participants aged 10 and older; primary endpoint fasting C-peptide change at 3 months; active, not recruiting, completion estimated 2028. Positive: supports the glycemic control item at Medium. Null: downgrades it to Low.
- **Randomized, double-masked alopecia areata trial versus minoxidil ([NCT04011748](https://clinicaltrials.gov/study/NCT04011748)):** About 20 participants; primary endpoint percentage hair regrowth at 1, 3 and 6 months; completion estimated 2027. Positive: first randomized efficacy evidence, moving hair regrowth to Medium. Null: weakens that item further.
- **US pilot ([NCT02624804](https://clinicaltrials.gov/study/NCT02624804)):** Completed 2024 with 8 treated participants; posted results cover safety only (one serious adverse event, depression), reported under Risks, without a peer-reviewed efficacy paper.
- **Chinese diabetes mechanism trial ([NCT03390231](https://clinicaltrials.gov/study/NCT03390231)):** Phase 2, 100 planned participants with type 1 or type 2 diabetes; completion was due 2020; status unknown, no results published.
- **Pediatric type 1 diabetes trial ([NCT01996228](https://clinicaltrials.gov/study/NCT01996228)):** 20 planned children aged 6–14; completion was due 2019; status unknown, no results published.
- **COVID-19 trial ([NCT04299152](https://clinicaltrials.gov/study/NCT04299152)):** Randomized phase 2, 20 planned participants; completion was due 2022; status unknown, no results published.
- **Independent replication:** No group outside the inventor's network has tested the therapy; a sham-controlled trial by another center would decide whether the type 1 diabetes signal ([Zhao 2012](https://pubmed.ncbi.nlm.nih.gov/22233865/)) holds or reflects bias.
- **Mechanism questions:** Whether benefit comes from CB-SC contact, platelet mitochondria ([Zhao 2017](https://pubmed.ncbi.nlm.nih.gov/28685960/)) or extracorporeal processing itself could strengthen or undermine the rationale; HLA antibody testing would clarify sensitization risk.

  
## Conclusion

Stem Cell Educator therapy is a one- or two-day procedure that passes a person's own white blood cells over donor cord blood stem cells before returning them. Its appeal is retraining, rather than suppressing, an immune system that attacks the body's own tissues.

The strongest signal concerns type 1 diabetes: one small study with a tiny comparison group reported better blood sugar control, lower insulin needs and more of the body's own insulin, but a later study by the same network saw this only in people who still made some insulin. Results in type 2 diabetes, immune-driven hair loss, long-lasting illness after coronavirus infection and bowel inflammation come from reports without comparison groups. Effects on healthy ageing have never been tested.

Reported harms are mostly those of a long blood-separation session, such as tingling, dizziness and arm discomfort, plus episodes of low blood sugar; serious events have been rare, but published reports cover few people, with limited long-term follow-up. Nearly all the evidence comes from the inventor and his company, whose financial stake is a conflict of interest, and the procedure is available only through trials or special access programs.

For a proactive adult living with a condition in which the immune system attacks the body, the picture is of a plausible but unconfirmed treatment whose short-term risks appear modest and whose benefits remain uncertain.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**
